Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Depreciation (2023 - 2024)

Contineum Therapeutics' Accumulated Depreciation history spans 2 years, with the latest figure at $1.7 million for Q4 2024.

  • Quarterly Accumulated Depreciation rose 16.25% to $1.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2024, up 16.25% year-over-year, with the annual reading at $1.7 million for FY2024, 16.25% up from the prior year.
  • Accumulated Depreciation came in at $1.7 million for Q4 2024, up from $1.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.7 million in Q4 2024 to a low of $1.5 million in Q4 2023.